<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

(Mark One)
[ X ]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
          EXCHANGE ACT OF 1934
                  For the quarterly period ended March 31, 2000

[   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
          EXCHANGE ACT OF 1934
               For the transition period from ________ to ________


                       Commission file number:  000-30267

                            ORCHID BIOSCIENCES, INC.
             (Exact name of registrant as specified in its charter)

        DELAWARE                                        22-3392819
(State or other jurisdiction                (I.R.S. Employer Identification No.)
of incorporation or organization)

  303 COLLEGE ROAD EAST, PRINCETON, NJ                     08540
(Address of principal executive offices)                 (Zip Code)

       Registrant's telephone number, including area code: (609) 750-2200


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.     Yes [   ]   No [X]

The number of shares outstanding of the registrant's Common Stock, $.001 par
value, as of  May 31, 2000, was 32,889,381.
<PAGE>

                            ORCHID BIOSCIENCES, INC.
                               INDEX TO FORM 10-Q



PART I FINANCIAL INFORMATION ...........................................  1

 Item 1. Financial Statements ..........................................  1

    Condensed Consolidated Balance Sheets as of March 31, 2000
    (unaudited) and December 31, 1999 ..................................  1
    Condensed Consolidated Statements Of Operations for the three
    months ended March 31, 2000 and 1999 (unaudited) ...................  4
    Consolidated Statements Of Cash Flows for the three months ended
    March 31, 2000 and 1999 (unaudited) ................................  5
    Notes To Condensed Consolidated Financial Statements (unaudited) ...  6

 Item 2. Management's Discussion And Analysis Of Financial Condition
         And Results Of Operations ..................................... 10

 Item 3. Quantitative And Qualitative Disclosures About Market Risk .... 13

PART II  OTHER INFORMATION ............................................. 15

 Item 1. Legal Proceedings ............................................. 15

 Item 2. Changes In Securities And Use Of Proceeds ..................... 15

 Item 3. Defaults Upon Senior Securities ............................... 15

 Item 4. Submission Of Matters To A Vote Of Security Holders ........... 15

 Item 5. Other Information ............................................. 16

 Item 6. Exhibits And Reports On Form 8-K .............................. 17

                                       i
<PAGE>

PART I   FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS


                            ORCHID BIOSCIENCES, INC.
                                AND SUBSIDIARIES

                     CONDENSED CONSOLIDATED BALANCE SHEETS
                 (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)

<TABLE>
<CAPTION>

                                                                                                              Pro Forma
                                                                                                              DECEMBER 31,
                                                                                 MARCH 31,   DECEMBER 31,          1999
                                                                                   2000         1999          (SEE NOTE 3)
                                                                                 ---------   ------------     -----------
                                                                                (UNAUDITED)                    (UNAUDITED)
<S>                                                                             <C>          <C>           <C>
                                    ASSETS
Current assets:
Cash and cash equivalents.......................................................  $ 50,880        $33,804       $33,804
Restricted cash.................................................................        --            400           400
Short-term investments..........................................................     2,800             --            --
Accounts receivable, net........................................................     2,791          2,102         2,102
Laboratory materials and supplies...............................................       212            182           182
Other current assets............................................................       957            859           859
                                                                                  --------        -------       -------
Total current assets............................................................    57,640         37,347        37,347
Deferred offering costs.........................................................     1,081             --            --
Equipment and leasehold improvements, net.......................................     9,803          9,474         9,474
Goodwill, net...................................................................    30,532         31,051        31,051
Other intangibles, net..........................................................    16,126         16,519        16,519
Other assets....................................................................     1,978            465           465
                                                                                  --------        -------       -------
Total assets....................................................................  $117,160        $94,856       $94,856
                                                                                  ========        =======       =======

                        LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)


Current liabilities:
Note payable--bank..............................................................  $     --        $ 1,000       $ 1,000
Current portion of long-term debt...............................................     1,071          1,141         1,141
Accounts payable................................................................     2,566          2,302         2,302
Accrued expenses................................................................     2,826          4,777         4,777
Due to related party............................................................        64             64            64
Deferred revenue................................................................       571            789           789
                                                                                  --------        -------       -------
Total current liabilities.......................................................     7,098         10,073        10,073
Long-term debt, less current portion............................................     3,851          4,122         4,122

Commitments and contingencies



Manditorily redeemable convertible preferred stock, $.001 par
 value (converts into 17,734,919 shares of common stock on an
 unaudited pro forma basis at December 31, 1999 upon
 consummation of the offering -- See note 11):
Series C, at redemption value, designated 2,493,692 shares; issued
 and outstanding 2,480,176 shares at March 31, 2000 and December 31,
 1999 (Aggregate liquidation value of $27,530 at March 31, 2000 and
 December 31, 1999).............................................................    27,530         27,530            --
Series E, designated 19,000,000 shares; issued and outstanding
 18,881,563 and 7,934,966 shares at March 31, 2000 and December 31, 1999,
  respectively (Aggregate liquidation value of $84,967 and $35,707 at                                                --
 March 31, 2000 and December 31, 1999, respectively)............................    90,990         39,035

Series E to be issued, at redemption value, (4,974,694 shares,
 including 518,534 shares subject to repurchase rights at
 December 31, 1999) (Aggregate liquidation value of
 $22,282 at December 31, 1999)..................................................        --         22,381            --
                                                                                  --------        -------       -------
                                                                                   118,520         88,946            --
                                                                                  --------        -------       -------
</TABLE>
     See accompanying notes to condensed consolidated financial statements.

                                       1
<PAGE>

                            ORCHID BIOSCIENCES, INC.
                                AND SUBSIDIARIES

               CONDENSED CONSOLIDATED BALANCE SHEETS--(CONTINUED)
                 (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)

<TABLE>
<CAPTION>
                                                                                                                PRO FORMA
                                                                                                              DECEMBER 31,
                                                                              MARCH 31,    DECEMBER 31,           1999
                                                                                2000            1999          (SEE NOTE 3)
                                                                              --------     ------------       ------------
                                                                             (UNAUDITED)                       (UNAUDITED)
<S>                                                                           <C>             <C>              <C>
Stockholders' equity (deficit):
 Preferred stock, $.001 par value. Authorized 23,400,000 shares;
  38,961 shares with no designation; no shares issued or
  outstanding ..........................................................       $    --          $    --           $    --
 Convertible preferred stock, $.001 par value (converts into
  1,074,740 shares of common stock on an unaudited pro forma
  basis at December 31, 1999 upon consummation of the
  offering -  See note 11):
  Series A, designated 1,200,000 shares; issued and outstanding
    970,900 shares at March 31, 2000
    and December 31, 1999 ..............................................               1                1              --
  Series B, designated 300,000 shares; issued and outstanding
    103,840 shares at March 31, 2000 and
    December 31, 1999 ..................................................            --               --                --
  Series D, designated 367,347 shares; no shares issued or
    outstanding ........................................................            --               --                --
 Common stock, $.001 par value. Authorized 30,000,000 shares;
  Issued and outstanding 1,196,450 and 845,450 shares at March 31,
   2000 and December 31, 1999, respectively (19,655,109 shares
  on an unaudited pro forma basis at December 31, 1999 upon
  conversion of the manditorily redeemable convertible
  preferred stock and the convertible preferred stock) .................               1                1                20

 Common stock to be issued (10,000 shares at
  December 31, 1999) ...................................................            --                 76                76
 Additional paid-in capital ............................................          58,408           50,325           139,253
 Deferred compensation .................................................         (12,405)          (7,930)           (7,930)
 Accumulated deficit ...................................................         (58,314)         (50,758)          (50,758)
                                                                               ---------        ---------         ---------
     Total stockholders' equity (deficit) ..............................         (12,309)          (8,285)           80,661
                                                                               ---------        ---------         ---------
     Total liabilities and stockholders' equity (deficit) ..............       $ 117,160        $  94,856         $  94,856
                                                                               =========        =========         =========
</TABLE>



     See accompanying notes to condensed consolidated financial statements.

                                       2
<PAGE>

                            ORCHID BIOSCIENCES, INC.
                                AND SUBSIDIARIES

                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                 (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
                                  (UNAUDITED)
<TABLE>
<CAPTION>
                                                                           Three months ended March 31,
                                                                          -----------------------------
<S>                                                                       <C>              <C>
                                                                             2000            1999
                                                                           --------        --------
Revenues:
  Product revenue ...................................................      $     545       $    --
  Laboratory testing ................................................          2,881            --
  Grant revenue .....................................................            292            --
  Contract revenue ..................................................           --               250
  License and other revenue .........................................            186            --
                                                                           ---------       ---------
     Total revenues .................................................          3,904             250
                                                                           ---------       ---------
Operating expenses:
  Cost of product revenue ...........................................            446            --
  Cost of laboratory testing ........................................          2,240            --
  Selling, general and administrative ...............................          4,943           1,635
  Research and development ..........................................          4,434           2,776
                                                                           ---------       ---------
     Total operating expenses .......................................         12,063           4,411
                                                                           ---------       ---------
Other income (expense):
  Interest income ...................................................            790              78
  Interest expense ..................................................           (111)             (5)
  Other expense .....................................................            (76)           --
                                                                           ---------       ---------
                                                                                 603              73
                                                                           ---------       ---------
     Net loss .......................................................         (7,556)         (4,088)
Beneficial conversion feature of preferred stock ....................         29,574            --
                                                                           ---------       ---------
     Net loss allocable to common stockholders ......................      $ (37,130)      $  (4,088)
                                                                           =========       =========
Basic and diluted net loss per share allocable to common
 Stockholders (note 1) ..............................................      $  (40.27)      $   (5.62)
                                                                           =========       =========
Shares used in computing basic and diluted net loss per share
 allocable to common stockholders (note 1) ..........................        921,920         726,978
                                                                           =========       =========
</TABLE>



     See accompanying notes to condensed consolidated financial statements.

                                       3
<PAGE>

                            ORCHID BIOSCIENCES, INC.
                                AND SUBSIDIARIES

                     CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (IN THOUSANDS)
                                  (UNAUDITED)
<TABLE>
<CAPTION>
                                                                                 Three months ended March 31,
                                                                                 ----------------------------
                                                                                      2000            1999
                                                                                    -------         -------
<S>                                                                                 <C>            <C>
Cash flows from operating activities:
 Net loss ....................................................................      $ (7,556)      $ (4,088)
 Adjustments to reconcile net loss to
    net cash used in operating activities:
  Noncash research and development expense ...................................         1,200           --
  Noncash compensation expense ...............................................           767             10
  Depreciation and amortization ..............................................         1,261            228
  Changes in assets and liabilities:
   Accounts receivable .......................................................          (688)           (20)
   Laboratory materials and supplies .........................................           (29)          --
   Deferred offering costs ...................................................        (1,081)          --
   Other current assets ......................................................           (98)          (710)
   Other assets ..............................................................           (14)          (140)
   Accounts payable ..........................................................           264          1,682
   Accrued expenses ..........................................................        (1,951)           165
   Due to related party ......................................................          --             (381)
   Deferred revenue ..........................................................          (218)          --
                                                                                    --------       --------
    Net cash used in operating activities ....................................        (8,143)        (3,254)
                                                                                    --------       --------
Cash flows from investing activities: ........................................          --
 Capital expenditures ........................................................          (679)        (3,649)
 Decrease in restricted cash .................................................           400           --
 Maturities of short-term investments ........................................          --            6,390
 Purchase of short term investments ..........................................        (2,800)          --
                                                                                    --------       --------
    Net cash used in (provided by) investing activities ......................        (3,079)         2,741
                                                                                    --------       --------
Cash flows from financing activities:
 Net proceeds from issuance of Series E manditorily
     redeemable convertible preferred stock ..................................        29,574           --
 Proceeds from issuance of debt from line of credit .........................           --              942
 Repayment of debt on lines of credit ........................................        (1,342)           (22)
 Proceeds from exercise of common stock options ..............................            66           --
                                                                                    --------       --------
    Net cash provided by financing activities ................................        28,298            920
                                                                                    --------       --------
Net increase in cash and cash equivalents ....................................        17,076            407
Cash and cash equivalents at beginning of period .............................        33,804            473
                                                                                    --------       --------
Cash and cash equivalents at end of period ...................................      $ 50,880       $    880
                                                                                    ========       ========
Supplemental disclosure of noncash financing and investing activities:
 Deferred compensation from issuance of restricted stock, grant of options and      $  5,242       $    250
  warrants ...................................................................
 Issuance of common stock for technology licenses ............................         1,200           --
 Issuance of common stock in connection with supply agreement ................         1,500           --
</TABLE>

     See accompanying notes to condensed consolidated financial statements.

                                       4
<PAGE>

                   ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                            March 31, 2000 and 1999
                                  (unaudited)
(1)  Basis of Presentation

  The accompanying unaudited condensed consolidated financial statements of
Orchid BioSciences, Inc. and subsidiaries (the "Company") have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete annual
financial statements. In the opinion of management, all adjustments, consisting
of normal recurring adjustments, considered necessary for a fair presentation
have been included. Interim results are not necessarily indicative of results
that may be expected for a full year.

  The accompanying unaudited condensed consolidated financial statements should
be read in conjunction with the audited consolidated financial statements and
footnotes thereto included in the Company's Registration Statement on Form S-1
(File No. 333-30774) filed with the Securities and Exchange Commission and
declared effective on May 4, 2000.

(2)  Net Loss Per Share

  Net loss per share is computed in accordance with SFAS No. 128, "Earnings Per
Share," by dividing the net loss allocable to common stockholders by the
weighted average number of shares of common stock outstanding. As of December
31, 1999 and March 31, 2000, the Company has certain options, warrants,
convertible preferred stock and mandatorily redeemable convertible preferred
stock, which have not been used in the calculation of diluted net loss per share
because to do so would be anti-dilutive. As such, the numerator and the
denominator used in computing both basic and diluted net loss per share
allocable to common stockholders for each year are equal. The Company has
reflected $29,573,564 as a beneficial conversion feature in the net loss
allocable to common stockholders for the quarter ended March 31, 2000 for the
5,971,903 shares of Series E mandatorily redeemable convertible preferred stock
("Series E stock") sold in January 2000.  The amount of the beneficial
conversion feature was calculated as the difference between the fair value of
the Company's common stock on the commitment date of $11.75 per share over the
conversion price of $4.50 per share, with a limitation that the beneficial
conversion feature can not exceed the gross proceeds received from the issuance
of the stock.

(3)  Pro Forma Balance Sheet

  Upon the closing of the Company's initial public offering (see note 11(a)) all
of the outstanding shares and shares to be issued of convertible preferred stock
and mandatorily redeemable convertible preferred stock at December 31, 1999
automatically converted into 18,809,659 shares of common stock and the
repurchase rights of certain Series E stock holders expired.  The December 31,
1999 unaudited pro forma balance sheet has been prepared assuming the conversion
of the convertible preferred stock outstanding and the mandatorily redeemable
convertible preferred stock outstanding and to be issued as of December 31,
1999, into common stock as of December 31, 1999.

(4)  GeneScreen, Inc. Pro Forma Financial Information

  The following unaudited pro forma financial information presents the combined
results of operations of Orchid and GeneScreen, Inc. ("GeneScreen") as if the
acquisition of GeneScreen by Orchid had occurred as of January 1, 1999, after
giving effect to certain pro forma adjustments, including amortization of
goodwill and other intangibles, and decreased interest expense from the
cancellation of Orchid's note payable to GeneScreen.  The pro forma financial
information does not necessarily reflect the results of operations that would
have occurred had Orchid and GeneScreen constituted a single entity during this
period or the results of operations which may occur in the future.

                                       5
<PAGE>

                                                       THREE MONTHS
                                                          ENDED
                                                        MARCH 31,
                                                           1999
                                                    ------------------

Revenues............................................      $ 3,545
Net loss allocable to common stockholders...........      $(4,976)
Basic and diluted net loss per share allocable
  to common stockholders............................      $ (6.84)

(5)    Employment Agreements

  Effective January 2000, we entered into three year employment agreements with
two executives of the Company.  In certain cases, the Company may be obligated
to pay the executive salary and benefits for up to eighteen months after leaving
the Company.

(6)  Sale of Convertible Preferred Stock

  In January 2000, the Company completed the sale of 5,971,903 shares of Series
E stock for gross proceeds of $29,573,564. The issuance of these securities
resulted in a $29,573,564 beneficial conversion feature which increase net loss
per share allocable to common stockholders in the first quarter of 2000. The
fair value of the Company's common stock on the commitment date was $11.75;
however, the amount of the beneficial conversion feature was limited to the
amount of gross proceeds received from the issuance of the Series E stock.  The
Company also issued 1,040,341 shares of Series E stock related to the conversion
of the Affymetrix convertible promissory note and for cash received by December
31, 1999 for which shares were not issued, and which was included in Series E
stock to be issued at December 31, 1999.

(7)  Stock Option Grants

  In January and on February 2, 2000, the Company granted 36,500, 679,400,
40,750 and 40,750 stock options under the 2000 Employee, Director and Consultant
Stock Plan at exercise prices of $1.25, $6, $12 and at the per share price of
the initial public offering (see note 11(a)), respectively, for which a
compensation charge of approximately $4.3 million will be recognized over the
respective vesting periods of the options. Some of these amounts result from
grants to consultants which are subject to remeasurement at the end of each
reporting period based upon the changes in the fair value of the common stock
until the consultant completes performance under the option agreement. In
addition, the Company issued 855,000 performance based stock options at exercise
prices of $6.00 for which compensation expense will be measured as the
difference between the fair value of our common stock at the time the
performance criteria is met and the external price and will be immediately
recorded as compensation expense.

  On March 31, 2000, the Company granted 289,660 stock options under the 1995
Stock Incentive Plan at exercise prices of $12 per share for which a
compensation charge of approximately $800,000 will be recognized over the
respective vesting periods of the options. Some of these amounts result from
grants to consultants which are subject to remeasurement at the end of each
reporting period based upon the changes in the fair value of the common stock
until the consultant completes performance under the option agreement.

(8)  2000 Employee, Director and Consultant Stock Incentive Plan

  On February 11, 2000 and March 17, 2000, respectively, the Board of Directors
and stockholders of the Company approved the 2000 Employee, Director and
Consultant Stock Incentive Plan ("Plan") for the issuance of common stock,
incentive stock options and non-qualified stock options to employees, directors
and consultants. The Board of Directors also authorized the granting of up to a
total of 1,500,000 options under this Plan and 3,500,000 under the 1995 Stock
Incentive Plan.

(9)  ABS Termination

  Effective February 15, 2000, the Company's Collaborative Development and
Marketing Agreement with Advanced Bioanalytical Services, Inc. ("ABS") was
terminated. The Company paid ABS $75,000 in full and final settlement of all
amounts owed under this agreement.

                                       6
<PAGE>

(10)  NEN Agreement

  On February 21, 2000, the Company entered into an Agreement for the License
and Supply of Terminators with NEN Life Science Products, Inc. ("NEN") pursuant
to which NEN has agreed to supply the Company with terminators for use in the
Company's SNPkits. In consideration of NEN's agreement to supply the Company
with terminators at favorable prices, the Company sold NEN 125,000 shares of its
common stock for a purchase price of $750,000 and paid NEN an up-front fee of
$750,000. The Company also agreed to pay NEN a certain percentage of net sales
revenue based on the number of SNPkits sold. The 125,000 shares had a fair value
of $1,500,000 on the date of the agreement. Since the products being supplied
are used in the Company's current products and may be used in future products,
the Company will defer and amortize the $750,000 up-front fee plus the $750,000
excess of the fair value of the issued common stock over the purchase price (or
a total of $1.5 million) over the estimated four year term of the agreement on a
straight-line basis. The Company measured the fair value of the common stock on
the date of the agreement as these shares were fully paid and nonforfeitable on
that date. The Company is required to purchase quantities of products with an
approximate minimum value during each annual period from the effective date as
follows: first year $333,000, second year $700,000, third year $990,000 and
fourth year $1,320,000. Either party can terminate the agreement any time after
four years from the commencement date, without cause, upon 90 days written
notice.

(11)  Subsequent Events

     (a)  Initial Public Offering

     In May 2000, the Company completed its initial public offering of 6,900,000
shares of common stock at a price of $8.00 per share (excluding underwriters'
discounts), generating net proceeds of approximately $49.8 million.  All shares
of Series A Convertible Preferred Stock ("Series A stock"), Series B Convertible
Preferred Stock ("Series B stock"), and Series E stock outstanding as of the
closing date of the offering were automatically converted into shares of common
stock on a one-for-one basis.  The 2,480,176 shares outstanding of Series C
Convertible Preferred Stock ("Series C stock") converted into 4,825,259 shares
of common stock.  No dividends were paid on any of the Series A, B, C, or E
stock.

     (b)  Change in Authorized Shares

     On May 10, 2000, the Company filed a restated certificate of incorporation
which increased its authorized shares of common stock to 50,000,000 shares,
revoked all existing preferred stock designations and authorized 5,000,000
shares of preferred stock. The Board of Directors has the authority, without any
further stockholder approval, to determine the price, privileges and other terms
of the shares of unissued preferred stock.

     (c)  Sarnoff Agreement

     On April 13, 2000, the Company amended its License and Option Agreement
with Sarnoff Corporation ("Sarnoff"). Under the terms of the amendment, in lieu
of all future cash payment, research funding, potential royalty payment and
stock issuance obligations, the Company made a payment to Sarnoff of
approximately $3 million and issued 250,000 shares of common stock and granted
five-year warrants to purchase 75,000 shares of common stock at an exercise
price of $8.00 per share. The Company exercised the remaining two option fields
on a non-exclusive basis as a result of this amendment. Previously, on February
2, 2000, the Company issued 100,000 shares of common stock to Sarnoff as an
advance on the issuances which would be owed in December 2000 for the two option
fields previously issued under the License and Option Agreement. As this
licensed technology has not reached technological feasibility and has no
alternative future uses, the cash payment of approximately $3.0 million and the
fair value of the equity securities of approximately $4.8 million will be
charged to research and development expense in the quarter ended June 30, 2000.

(12) Recent Accounting Announcements

  In December 1999, the staff of the Securities and Exchange Commission issued a
Staff Accounting Bulletin ("SAB") No. 101, "Revenue Recognition in Financial
Statements" ("SAB 101"). SAB 101 summarizes certain of the staff's views in
applying generally accepted accounting principles to revenue recognition in
financial statements, including the recognition of non-refundable fees received
upon entering into arrangements. Our revenue recognition

                                       7
<PAGE>

policies are consistent with the provisions of SAB 101 and our financial
statements reflect this policy for all periods presented.

(13)  Legal Matters

  The Company is not a party to any material legal proceeding.  The Company is
engaged in discussions with Motorola, Inc. ("Motorola") in an attempt to resolve
certain areas of disagreement that have arisen under the existing collaboration
in the area of microfluidics.  The primary issue of disagreement between the
parties relates to whether, under the terms of the agreement with Motorola,
Motorola has a right to obtain a license to the Company's SNP-IT technology for
use with Motorola's microfluidic chips.  While the Company believes that, under
the terms of the agreement, Motorola has no rights to its SNP-IT technology,
there can be no assurance that an agreement can be reached with Motorola on this
issue or that the Company would prevail if this dispute were to develop into
arbitration or litigation.  Nonetheless, the Company believes that, even if it
fails to successfully resolve this issue or to prevail in any such arbitration
or litigation, it would only be obligated to grant Motorola a non-exclusive
license to use its SNP-IT technology with their microfluidic chips on terms no
less favorable than those offered to other licensees.  The Company does not
believe that such a result is likely to have a material adverse affect on the
Company's business, financial condition and operating results.

(14)  Self-Insurance Reserve

  GeneScreen Inc., the Company's wholly owned subsidiary, is self-insured for
the risk of loss relating to certain litigation claims that might arise from
GeneScreen's testing results. However, due to provisions in certain service
contracts, GeneScreen is insured for claims arising from testing performed under
the Texas, Ohio and Arizona contracts. Insurance coverage began in 1995 for
testing under the Texas contract, in 1997 for testing under the Ohio and Arizona
contracts and all other contracts in August 1998. Management estimates future
litigation costs based on historical litigation experience. The accrued
litigation reserve for the self-insured risk at March 31, 2000 was $176,000.

(15)  Segment Information

  The Company operates in two segments, each of which are strategic businesses
that are managed separately because each business develops, manufactures and
sells distinct products and services.  The segments and a description of their
business are as follows:  (i) the Company prior to the acquisition of GeneScreen
("Orchid"), which performs SNP scoring analysis and markets related equipment
and consumables; and (ii) GeneScreen, which performs DNA laboratory analysis for
paternity, transplantation and forensic testing.

  The Company evaluates performance of and allocates resources to the segments.
Prior to the acquisition of GeneScreen on December 30, 1999, the Company was
operated and managed as one business.  Segment information as of and for the
quarter ended March 31, 2000 for Orchid and GeneScreen is as follows:

                                          Orchid   GeneScreen    Total
                                         --------  -----------  --------

     Revenues from external customers      1,023        2,881     3,904
     Segment net loss                     (6,614)        (942)   (7,556)
     Total assets                        115,861        1,299   117,160

                                       8
<PAGE>

                            ORCHID BIOSCIENCES, INC.

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

  This Management's Discussion and Analysis of Financial Condition and Results
of Operations as of March 31, 2000 and for the three month periods ended March
31, 2000 and 1999 should be read in conjunction with the sections of our
Registration Statement on Form S-1 filed with the Securities and Exchange
Commission and declared effective on May 4, 2000, as amended, entitled
"Management's Discussion and Analysis of Financial Condition and Results of
Operations."  The following discussion of the financial condition and results of
our operations should be read in conjunction with our Condensed Consolidated
Financial Statements, including the Notes thereto, included elsewhere in this
Form 10-Q. This Form 10-Q contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended, and Section
27A of the Securities Act of 1933, as amended. When used in this report or
elsewhere by management from time to time, the words "believe," "anticipates,"
"intends," "plans," "estimates," and similar expressions are forward looking
statements. Such forward looking statements contained herein are based on
current expectations. Prospective investors are cautioned that any such forward-
looking statements are not guarantees of future performance and involve risks
and uncertainties. Actual events or results may differ materially from those
discussed in the forward-looking statements as a result of various factors. For
a more detailed discussion of such forward looking statements and the potential
risks and uncertainties that may impact upon their accuracy, see the "Forward
Looking Statements" section of this Management's Discussion and Analysis of
Financial Condition and Results of Operation and also the potential risks and
uncertainties set forth in the "Overview" section hereof and in the "Risk
Factors" section of our final prospectus dated May 4, 2000, comprising a part of
our Registration Statement on Form S-1 filed with the Securities and Exchange
Commission. Except as required by law, we undertake no obligations to update any
forward looking statements. You should also carefully consider the factors set
forth in other reports or documents that we file from time to time with the
Securities and Exchange Commission.

OVERVIEW

  We are engaged in the development and commercialization of genetic diversity
technologies, products and services. Since we began operations in March 1995, we
have devoted substantially all of our resources to the development and
application of a portfolio of products and services using our proprietary
biochemistry for scoring SNPs and microfluidics technologies for applications in
drug discovery, principally in the field of pharmacogenetics and DNA synthesis.

  On December 30, 1999, we acquired GeneScreen, Inc. for a net purchase price of
$42.7 million consisting of a combination of cash and shares of our Series E
mandatorily redeemable convertible preferred stock, offset by the cancellation
of certain debt owed to GeneScreen. We included $28.5 million as a beneficial
conversion feature in the purchase price. The amount of the beneficial
conversion feature was calculated as the difference between the $11.75 per share
fair value of our common stock on December 22, 1999, the commitment date which
was the date of the merger agreement for the acquisition, over the $4.50 per
share conversion price of the stock. GeneScreen is a company engaged in DNA
laboratory analysis for paternity, forensics and transplantation testing and had
revenues of approximately $13.7 million in 1999. In connection with the
acquisition of GeneScreen, we recorded approximately $43.1 million of goodwill
and other intangible assets, which we will amortize over periods ranging from 4
to 15 years.

  Most of our current activities and resources are directed toward
commercializing our SNP scoring products and services which apply our
proprietary SNP-IT primer-extension technology. We expect to recognize revenues
from the sale of both our SNPstream instrument systems and our SNPware
consumables. We also expect each SNPstream system we sell or lease will generate
a recurring revenue stream from the sale of our SNPware consumables. We also
provide, or plan to provide, a variety of genetic diversity services to the
pharmaceutical and biotechnology industries through our ultra high-throughput
MegaSNPatron facility.

  GeneScreen's established business in paternity testing, forensics and
transplantation supports our goal of building our business in genetic diversity.
We believe our SNP-IT and microfluidics technologies will be able to improve the
performance of GeneScreen's genetic testing laboratories. We plan on using the
clinically approved laboratories at GeneScreen to expand our SNP scoring
services to pharmacogenetics testing of patient samples in

                                       9
<PAGE>

pharmaceutical clinical trials. We also plan on using these laboratories to
conduct SNP scoring services offered via the Internet.

  GeneScreen's DNA testing business is dependent upon contracts with various
states and counties to provide paternity testing. These contracts are generally
put out to bid by each respective state every one to three years. The contract
bidding process is highly competitive and the award varies from state to state.
Some states and counties award contracts solely based on the lowest price while
others use a scoring matrix to achieve the desired mix of price, quality and
service. GeneScreen derives its transplantation business through contracts on a
bid basis with the National Marrow Donor Program, a not-for-profit agency that
facilitates hematopoietic cell transplants through organizing volunteer donor
drives, maintaining a national donor registry and other educational services.
With the acquisition of GeneScreen, we expect to generate service revenue in
fiscal year 2000 and use GeneScreen's CLIA approved testing laboratories to
expand our genetic diversity testing business and services.

  Our ability to achieve profitability will depend in part on our ability to
successfully develop and commercialize our proprietary SNP scoring and
microfluidics technologies in the form of products and services for
pharmaceutical and biotechnology companies and research institutions. We
introduced our SNPstream 25K SNP-IT-based SNP scoring system, SNPware
consumables and related services in late 1999. We intend to develop additional
models of SNPstream instruments with lower throughput capabilities. Because our
proprietary SNP-IT primer-extension technology is very adaptable to other
hardware platforms, we intend to offer our SNPware kits for use on instruments
made or sold by other companies. Our collaboration with Affymetrix, Inc. is an
example of this platform propagation strategy.

  We based our proprietary SNP value creation strategy on the creation of
proprietary rights covering the identification of SNPs and their associations to
medically important attributes of patients. We intend to develop intellectual
property rights in this area through collaborations with members of our Clinical
Genetics Network, pharmaceutical and biotechnology companies. We do not expect
royalties from commercial sale or license of intellectual property rights
generated by using our technologies for at least several years, if at all.

  We have incurred losses since inception, and, as of March 31, 2000, we had a
total stockholders' deficit of $12.3 million, including an accumulated deficit
of $58.3 million. We anticipate incurring additional losses over at least the
next several years. We expect these losses to continue as we expand the
commercialization of our products and services to the research market and we
fully implement our proprietary SNP value creation business strategies. We
expect this expansion to result in increases in research and development,
marketing and sales, and general and administrative expenses. Payments under
strategic alliances, collaborations and licensing arrangements will be subject
to significant fluctuation in both timing and amount and therefore our results
of operations for any period may not be comparable to the results of operations
for any other period.

RESULTS OF OPERATIONS

Three Months Ended March 31, 2000 and 1999

Revenue. Revenue for the three months ended March 31, 2000 of $3.9 million
represented an increase of $3.6 million or 1,200% compared to $.3 million for
the first three months of 1999. The increase was largely due to the addition of
our GeneScreen DNA testing operations and the sales of our SNPstream(TM) 25K
instrument systems and SNPware(TM) consumables. The results of operations for
the quarter ended March 31, 1999 do not include those of GeneScreen, Inc., which
we acquired on December 30, 1999.

Cost of product revenue.  Cost of product revenue for the three months ended
March 31, 2000 was $.4 million for the first three months of 1999.  The increase
was attributable to the cost of SNPstream instrument and consumables sold, in
the first three months of 2000.  There were no sales for the quarter ended March
31, 1999.

Cost of laboratory testing.  Cost of laboratory testing was $2.2 million for the
three months ended March 31, 2000.  The increase was attributable to the
acquisition of GeneScreen in December 1999, which provided 100% of the
laboratory testing.

Selling, general and administrative expenses.  Selling, general and
administrative expenses for the three months ended March 31, 2000 were $4.9
million, an increase of $3.3 million or 206%, compared to $1.6 million for the
first

                                       10
<PAGE>

three months of 1999. The increase was primarily attributable to the expansion
of administration facilities and the hiring of additional personnel as we
increased our executive and administrative staffing in anticipation of becoming
a public company and supporting our future growth, amortization of deferred
compensation expense and operating costs related to GeneScreen which was
acquired in December 1999.

Research and development expenses.  Research and development expenses for the
three months ended March 31, 2000 of $4.4 million represented an increase of
$1.6 or 57%, compared to $2.8 million for the first three months of 1999.  The
increase in collaborative research and development expenses was primarily
attributable to increased expenses as we hired additional research and
development personnel, increased purchases of laboratory supplies, increased
equipment depreciation, amortization of deferred compensation expense, increased
facilities expenses in connection with the expansion of our internal and
collaborative research efforts and the issuance of 100,000 shares of common
stock to Sarnoff Corporation as an advance on the issuances that would have been
owed in December 2000 under a License and Option Agreement.  Future research and
development expenses are expected to increase as additional personnel are hired
and research and development facilities are expanded to accommodate our
strategic collaborations and internal research.

Other income (expense).  Other income (expense) for the three months ended March
31, 2000 of $.6 million increased $.5, or 500%, compared to other income,
(expense) of $.1 million for the first three months of 1999. This increase was
primarily due to interest received on larger cash, cash equivalent and short-
term investment balances which we held as a result of our receipt of proceeds
from our Series E private placement in December 1999 and January 2000.

Net loss allocable to common stockholders.  Due to the factors discussed above,
for the three months ended March 31, 2000, we reported a net loss allocable to
common stockholders of $37.1 million as compared to $4.1 million in the first
three months of 1999.  Net loss per share allocable to common stockholders
includes a beneficial conversion feature on preferred stock for the three months
ended March 31, 2000 of $29.6 million.

LIQUIDITY AND CAPITAL RESOURCES

  Since our inception, we have financed our operations primarily through
research and development funding from collaborative partners and two private
placements of equity securities that closed in March 1998 and in December 1999
and January 2000 with aggregate net proceeds from the private placements of
approximately $102 million. The sale of the Series E mandatorily redeemable
convertible preferred stock in December 1999 resulted in a $44,554,000
beneficial conversion feature which is included in net loss allocable to common
stockholders in 1999. The closing of Series E mandatorily redeemable convertible
preferred stock in January 2000 resulted in an additional $29,573,564 beneficial
conversion feature which is included in net loss allocable to common
stockholders and net loss per share allocable to common stockholders in the
first quarter of 2000. In December 1998, we obtained a secured $6.0 million
equipment line of credit, for the purchase of plant and equipment at our
corporate headquarters and research and development laboratories. At December
31, 1999, this funding commitment expired and at March 31, 2000 we had
borrowings of $4.4 million outstanding under this facility. We lease our
corporate and primary research facility under an operating lease which expires
in 2008.

  As part of our transition from a business model based on microfluidics
technologies to one based on SNP scoring technologies, on April 13, 2000 we
amended our License and Option Agreement with Sarnoff by making a single payment
of approximately $3.0 million, issuing 250,000 shares of common stock and
delivering a five-year warrant to purchase 75,000 shares of our common stock at
an exercise price of $8.00 per share. Previously on February 2, 2000, we issued
100,000 shares of common stock to Sarnoff as an advance on the issuances which
would be owed in December 2000 for the two option fields previously exercised
under the License and Option Agreement. As the licensed technology has not
reached technological feasibility and has no alternative uses, the cash payment
of approximately $3.0 million and the fair value of the equity securities of
approximately $4.8 million will be charged to research and development expense
in 2000.

  As of March 31, 2000, we had $53.7 million in cash and cash equivalents and
short-term investments, compared to $33.8 million as of December 31, 1999. This
increase primarily reflects the completion of our private placement of equity
securities. In addition, our initial public offering in May 2000 generated
approximately $49.8 million of proceeds, net of underwriting discounts and
commissions and offering expenses, from the sale of a total of 6,900,000 shares
of common stock, including the underwriters' over-allotment shares. To date,
inflation has not had

                                       11
<PAGE>

a material effect on our business. We believe that our cash reserves, expected
short-term revenue, and the net proceeds of the initial public offering
completed in May 2000 will be sufficient to fund our operations through at least
the next 18 months. We may need to access the capital markets for additional
financing to operate our ongoing business activities.

  Net cash used in operations for the quarter ended March 31, 2000 was
approximately $8.1 million compared with approximately $3.3 million for the
comparable period in 1999.  Non-cash charges in 2000 included compensation
expense of $0.8 million and research and development expense from the issuance
of equity securities of $1.2 million and depreciation and amortization expense
of $1.3 million.  Investing activities included $0.7 million in cash used during
the quarter ended March 31, 2000 for equipment purchases and $2.8 million for
the purchases of short term investments.  Financing activities included the use
of $1.3 million to repay debt from lines of credit.

  Working capital increased to approximately $50.5 million at March 31, 2000
from approximately $27.3 million at December 31, 1999.  The increase in working
capital was primarily due to our Series E mandatorily redeemable convertible
preferred stock financing in January 2000.

  We cannot assure you that our business or operations will not change in a
manner that would consume available resources more rapidly than anticipated. We
also cannot assure you that we will not require substantial additional funding
before we can achieve profitable operations. Our capital requirements depend on
numerous factors, including the following:

 - our ability to enter into strategic alliances or make acquisitions;

 - regulatory changes and competing technological and market developments;

 - changes in our existing collaborative relationships;

 - the cost of filing, prosecuting, defending and enforcing patent claims and
   other intellectual property rights;

 - the purchase of additional capital equipment;

 - the development of our SNPstream and DNAstream and software product lines and
   associated reagent consumables;

 - the development of our SNPware consumables and kits;

 - the success rate of establishing new contracts, and renewal rate of existing
   contracts, for DNA testing services in the areas of paternity, forensics and
   transplantation;

 - the progress of our existing and future milestone and royalty producing
   activities; and

 - the availability of additional funding, if necessary, and if at all, on
   favorable terms.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

  Our exposure to market risk is principally confined to our cash equivalents
and short-term investments, all of which have maturities of less than one year.
We maintain a non-trading investment portfolio of investment grade, liquid debt
securities that limits the amount of credit exposure to any one issue, issuer or
type of instrument.  The fair value of these securities approximates their cost.

FORWARD LOOKING STATEMENTS

  This report may contain forward-looking statements. Such statements are based
on management's current expectations and are subject to a number of factors and
uncertainties that could cause actual results or outcomes to differ materially
from those described in such forward-looking statements. These statements
address or may address the following subjects: results of operations, customer
growth and retention; development of technology; losses or earnings; operating
expenses, including, without limitation, marketing expense
                                       12
<PAGE>

and technology and development expense; and revenue growth. We caution investors
that there can be no assurance that actual results, outcomes or business
conditions will not differ materially from those projected or suggested in such
forward- looking statements as a result of various factors, including, among
others, our limited operating history, unpredictability of future revenues and
operating results, and competitive pressures. For further information, refer to
the more specific factors and uncertainties discussed throughout this report.

                                       13
<PAGE>

PART II  OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS.

  We are not a party to any material legal proceedings. We are engaged in
discussions with Motorola in an attempt to resolve certain areas of disagreement
that have arisen under our existing collaboration in the area of microfluidics.
The primary issue of disagreement between the parties relates to whether, under
the terms of our agreement, Motorola has a right to obtain a license to our SNP-
IT technology for use with Motorola's microfluidic chips. While we believe that,
under the terms of our agreement, Motorola has no rights to our SNP-IT
technology, we cannot assure you that we can reach agreement with Motorola on
this issue or that we would prevail if this dispute were to develop into
arbitration or litigation. Furthermore, we are likely to incur substantial costs
and expend substantial personnel time in resolving this issue if it becomes the
subject of arbitration or litigation. Nonetheless, we believe that, even if we
fail to successfully resolve this issue or to prevail in any such arbitration or
litigation, we would only be obligated to grant Motorola a non-exclusive license
to use our SNP-IT technology with their microfluidic chips on terms no less
favorable than those offered to other licensees. We do not believe that this
result is likely to have a material adverse affect on our business or financial
condition results of operations.

ITEM 2.  CHANGES IN SECURITIES AND USE OF PROCEEDS.

     (a) In December 1999 and January 2000, we privately placed an aggregate of
18,881,563 shares of our Series E convertible preferred stock and received net
proceeds of approximately $85.5 million.  In May 2000, we completed our initial
public offering of 6,900,000 shares of our common stock and received net
proceeds of approximately $49.8 million.

     (b) In February 2000, twelve individuals exercised options to purchase an
aggregate of 45,632 shares of our common stock for an aggregate purchase price
of $45,583.

     (c) In March 2000, thirteen individuals exercised options to purchase an
aggregate of 65,002 shares of our common stock for an aggregate purchase price
of $18,399.

     No underwriters were involved in the foregoing offers and sales of
securities. Such offers and sales were made in reliance upon an exemption from
the registration provisions of the Securities Act of 1933, as amended (the
"Securities Act"), set forth in Section 4(2) thereof relative to sales by an
issuer not involving any public offering or the rules and regulations
thereunder, or in the case of the exercise of options to purchase common stock,
Rule 701 under the Securities Act. All of the foregoing securities are deemed
restricted securities for purposes of the Securities Act.

  We intend to use approximately $4 million of the net proceeds for capital
expenditures associated with technology and systems upgrades and expansion of
our headquarters.  We have no specific plan at this time for use of the
remaining proceeds and expect to use such proceeds for working capital and
general corporate purposes including the payment of sales and marketing
expenses.  We may, when the opportunity arises, use an unspecified portion of
the net proceeds to acquire or invest in complementary businesses, products and
technologies.  From time to time, in the ordinary course of business, we expect
to evaluate potential acquisitions of such businesses, products or technologies.
However, we have no present understandings, commitments or agreements with
respect to any material acquisition.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

     Not applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

     On March 17, 2000, we held our annual meeting of stockholders.  At the
meeting, our stockholders elected Sidney M. Hecht, Ph.D., Samuel D. Isaly,
Jeremy M. Levin, D.Phil., MB.Bchir., Dale R. Pfost, Ph.D., Robert M. Tien, M.D.,
M.P.H. and Anne M. VanLent to serve as our Directors.  The stockholders also
approved our Restated Certificate of Incorporation, Amended and Restated Bylaws
and 2000 Employee, Director and Consultant Stock Plan.  In addition, our
stockholders increased the shares of common stock reserved for issuance under
the 1995 Stock Incentive Plan to 3,500,000, reserved 1,500,000 shares of common
stock for issuance under the 2000

                                       14
<PAGE>

Employee, Director and Consultant Stock Plan and ratified the Board of
Director's appointment of KPMG LLP to serve as our independent public
accountants for the fiscal year ending December 31, 2000. 25,004,784 shares
voted in favor of each resolution. There were no votes against any proposal and
there were no abstentions.

     On February 16, 2000, certain stockholders acted by written consent in lieu
of a special meeting to amend our Certificate of Incorporation to change our
corporate  name from Orchid Biocomputer, Inc. to Orchid BioSciences, Inc.  There
were no votes against the amendment and there were no abstentions.

ITEM 5.  OTHER INFORMATION.

     Not applicable.

                                       15
<PAGE>

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.

          (a)  Exhibits
               --------

          The following is a list of exhibits filed as part of this Quarterly
Report on Form 10-Q.

Exhibit
Number    Description
------    -----------

3.1       Restated Certificate of Incorporation

4         Specimen Stock Certificate (filed as Exhibit 4.1 to the Registrant's
          Registration Statement on Form S-1, No. 333-30774)

10.1      1995 Stock Incentive Plan, as amended, including form of stock option
          certificate for incentive and non-statutory stock options (filed as
          Exhibit 10.1 to the Registrant's Registration Statement on Form S-1
          No. 333-30774)

10.2      2000 Employee, Director, Consultant Stock Plan, including form of
          stock option agreement for non-statutory and incentive stock options
          (filed as Exhibit 10.2 to the Registrant's Registration Statement on
          Form S-1, No. 333-30774)

10.3      Executive Benefit Program, including Executive Deferred Compensation
          Plan Executive and Severance Plan (filed as Exhibit 10.3 to the
          Registrant's Registration Statement on Form S-1, No. 333-30774)

10.6      License and Option Agreement, dated December 10, 1997, between Sarnoff
          Corporation and the Registrant, as amended by Amendment to License and
          Option Agreement dated as of April 13, 2000 by and between Sarnoff
          Corporation and the Registrant (filed as Exhibit 10.6 to the
          Registrant's Registration Statement on Form S-1, No. 333-30774)

10.7      Employment Agreement, effective as of January 1, 2000, by and between
          the Registrant and Dale R. Pfost, Ph.D. (filed as Exhibit 10.7 to the
          Registrant's Registration Statement on Form S-1, No. 333-30774)

10.8      Employment Agreement, effective as of January 1, 2000, by and between
          the Registrant and Donald R. Marvin. (filed as Exhibit 10.8 to the
          Registrant's Registration Statement on Form S-1, No. 333-30774)

10.9      Agreement  for the License and Supply of Terminators, dated February
          16, 2000 between the Registrant and NEN Life Science Products, Inc.
          (filed as Exhibit 10.9 to the Registrant's Registration Statement on
          Form S-1, No. 333-30774)

27        Financial Data Schedule

          (b)  Reports on Form 8-K
               -------------------

          No reports on Form 8-K have been filed during the three months ended
March 31, 2000.

                                       16
<PAGE>

                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                    ORCHID BIOSCIENCES, INC.



Date: June 19, 2000                 By:  /s/ Donald R. Marvin
                                         ------------------------------------
                                         DONALD R. MARVIN
                                         Senior Vice President, Chief Operating
                                         Officer, Chief Financial Officer
                                         (principal financial and accounting
                                         officer)

                                       17